• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    Homology Gets Fast Track Designation for Gene Therapy Candidate

    Jocelyn Aspa
    May. 14, 2019 03:30PM PST
    Genetics Investing
    NASDAQ:FIXX

    The fast track designation comes several weeks after the FDA granted the company an investigational new drug application for HMI-102.

    Just weeks after Homology Medicines (NASDAQ:FIXX) received investigational new drug clearance from the US Food and Drug Administration (FDA) for its gene therapy candidate, HMI-102, the company revealed on Tuesday (May 14) that the regulatory agency has now granted the candidate fast track designation.

    HMI-102, which is a one time gene therapy drug to treat adults with phenylketonuria (PKU), received the fast track nod from the FDA as PKU is considered a rare and serious genetic disease.

    According to the FDA, fast track designation is primarily awarded to drugs or biologics that aim to treat life-threatening and serious diseases and have the potential to deal with unmet medical needs.

    PKU occurs when patients are born without the ability to break down phenylalanine, which is an amino acid found in a wide range of foods and drinks containing protein and strong sweeteners. If the condition goes untreated, it can leave patients with severe neurological damage.

    “We believe FDA’s decision to grant Fast Track designation is a positive step forward for the development of HMI-102, which is designed to treat the underlying cause of this disease and allow freedom from a restrictive diet, the current standard of care,” Arthur Tzianabos, Ph.D, president and CEO of Homology Medicines, said in a press release.

    Tzianabos added that his company has been working over the last three years on pushing its dual gene therapy and gene editing platform towards providing care to patients with PKU and other rare conditions.

    While the FDA granted the investigational new drug application for HMI-102 in April, the company previously received orphan drug designation for the candidate in the US and the European Union for the use of the human hematopoietic stem cell-derived adeno-associated virus AAVHSC15 to treat PAH deficiency. Severe deficiency of the PAH gene is the main cause of PKU.

    Homology Medicines is currently looking to start pheNIX, its Phase 1/2 trial for adult patients with PKU, and expects initial clinical data sometime this year.

    Tuesday’s announcement comes on the heels of the company revealing its Q1 2019 financial results on Monday (May 13). In its results, Homology Medicines highlights a net loss of US$23.29 million for the quarter as compared to US$10.2 million for the same quarter in 2018.

    The company notes that its HMI-103 candidate, which is an in vivo gene editing candidate for child patients with PKU, has also begun investigational new drug-enabling studies.

    Since Monday’s open, shares of Homology Medicines have increased 1.66 percent to close at US$22.65 on Tuesday. The company currently has a “strong buy” ranking on TipRanks based off three analyst ratings with an average price target of US$32.50, a high estimate of US$36 and a low of US$29.

    Don’t forget to follow us @INN_LifeScience for real-time news updates

    Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.

    nasdaq:fixxhomology medicines
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Genetics Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×